Partial
Partially Aligned
Patient Risk:
Low
Summary
Most mechanistic/antagonism statements are generally consistent with the provided label excerpts on mechanism of action and orexin receptor antagonism, but the response includes many mechanistic specifics (e.g., exact OX1 vs OX2 targeting) and broader claims about orexin’s physiological role and downstream effects that are not explicitly supported in the provided excerpts.
Category Scores
Accurate Statements
Dayvigo’s active ingredient is lemborexant.
Active ingredient lemborexant is reflected in the label excerpt under Drug/Active ingredient and clinical pharmacology (mechanism of action of lemborexant).
Lemborexant treats insomnia by blocking the brain’s wake-promoting orexin (hypocretin) signaling.
Indication for insomnia (Section 1) and mechanism presumed through antagonism of orexin receptors (Section 12.1).
Lemborexant antagonizes orexin receptors.
Mechanism of action presumed to be through antagonism of orexin receptors (Section 12.1) and competitive antagonist at orexin receptors (Section 12.2).
Lemborexant’s pharmacology involves orexin receptor antagonism.
Mechanism of action and pharmacodynamics describing orexin receptor antagonism (Sections 12.1 and 12.2).
Orexin receptor antagonism by lemborexant blocks wake-promoting orexin pathways.
Orexin receptor antagonism (Sections 12.1 and 12.2) and insomnia indication (Section 1).
Orexin receptor antagonism by lemborexant reduces insomnia symptoms.
Insomnia efficacy for DAYVIGO in clinical trials (Section 14.1) combined with mechanism of action via orexin receptor antagonism (Sections 12.1/12.2).
Unsupported Statements
Orexins help keep the brain in a wake state.
Provided excerpts do not explicitly state orexins’ physiological role in maintaining wakefulness.
When lemborexant blocks orexin receptors, it reduces wakefulness.
Label excerpts discuss impairment of daytime wakefulness as an effect of DAYVIGO (Section 5.1) but do not explicitly tie that effect to “reduces wakefulness” phrasing from receptor blockade.
When lemborexant blocks orexin receptors, it makes it easier to fall asleep.
The label excerpt indicates difficulty with sleep onset and/or sleep maintenance as the insomnia phenotype and shows clinical superiority, but the provided excerpt does not explicitly attribute effects to receptor blockade causing easier sleep onset.
When lemborexant blocks orexin receptors, it makes it easier to stay asleep.
Same issue as sleep-onset; provided excerpts do not explicitly connect receptor blockade to specific sleep maintenance wording.
Lemborexant specifically targets OX1 receptors.
Label excerpt states lemborexant binds to OX1R (Section 12.2), but the response’s wording “specifically targets” is more specific than the excerpted language (binding/acts as antagonist to OX1R is supported; “specifically targets” is not explicitly stated).
Lemborexant specifically targets OX2 receptors.
Same issue as OX1; supported that it binds to OX2R, but “specifically targets” is not explicitly used in the provided excerpts.
By inhibiting both OX1 and OX2 receptor types, lemborexant prevents orexin signaling from promoting arousal.
Label excerpt supports binding to OX1R and OX2R and that it is an antagonist (Section 12.2), but the provided excerpts do not explicitly state “prevents orexin signaling from promoting arousal.”
Orexin neurons are involved in stabilizing wakefulness.
Provided excerpts do not discuss orexin neuron roles in stabilizing wakefulness.
Orexin neurons help prevent inappropriate sleep.
Provided excerpts do not discuss orexin neuron roles in preventing inappropriate sleep.
When an orexin receptor antagonist like lemborexant blocks orexin receptors, the arousal system is less able to maintain wakefulness.
The label excerpt discusses daytime wakefulness impairment as a CNS depressant effect (Section 5.1), but does not explicitly describe the arousal system maintaining wakefulness.
When an orexin receptor antagonist like lemborexant blocks orexin receptors, it shifts the brain toward sleep.
The provided excerpts do not contain this explicit mechanistic outcome phrasing.
Dayvigo is not the same class as many sedatives that directly enhance GABA-A activity.
Provided excerpts do not discuss comparative class or GABA-A activity.
Dayvigo does not broadly amplify inhibitory neurotransmission.
Provided excerpts do not discuss inhibitory neurotransmission broadly.
Dayvigo works by shutting down orexin-driven arousal signaling.
Mechanism of action is presumed to be antagonism of orexin receptors (Section 12.1) but the excerpt does not explicitly use the “shutting down orexin-driven arousal signaling” phrasing.
Orexin receptor antagonism by lemborexant blocks wake-promoting orexin pathways.
Partially supported (orexin receptor antagonism and insomnia indication), but the specific “wake-promoting orexin pathways” phrasing is not explicitly stated in the provided excerpts.
Orexin receptor antagonism by lemborexant blocks wake-promoting orexin pathways.
Not explicitly supported as phrased; see label support is general antagonism.
Contradictions
Important Omissions
No dosage and administration details were evaluated against the label (e.g., 5 mg once nightly immediately before bed with at least 7 hours remaining; maximum 10 mg; meal-related delay; CYP3A inhibitor/inducer dose adjustments/avoidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response is largely mechanistic and efficacy-related; it does not state dosing, contraindications, or safety warnings from the label. While some mechanistic specifics are not explicitly supported by the provided excerpts, no direct contraindication-dosing conflict or label contradiction is present in the claims provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple mechanistic statements about orexin physiology and downstream effects are not explicitly supported by the provided label excerpts, and some wording (e.g., “specifically targets”) is more specific than the label language provided.
Suggested Improvement
Limit mechanistic claims to what the excerpts state: antagonism of orexin receptors (presumed mechanism) and binding to OX1R and OX2R as a competitive antagonist (Section 12.2). Avoid additional unquoted functional assertions (e.g., orexin neuron roles in stabilizing wakefulness or “shifts the brain toward sleep”) unless supported by label text.